Diabetic Retinopathy Pipeline Insight Report 2023 (Updated)
DelveInsight’s, “Diabetic Retinopathy Pipeline Insight 2023,” report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in the Diabetic Retinopathy pipeline landscape. It covers the Diabetic Retinopathy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Diabetic Retinopathy Pipeline Report
- DelveInsight’s Diabetic Retinopathy pipeline report depicts a robust space with 50+ active players working to develop 55+ pipeline therapies for Diabetic Retinopathy treatment.
- The leading companies working in the Diabetic Retinopathy market include Kodiak Sciences, Novartis, Regenxbio Inc., OcuTerra Therapeutics, Ocular Therapeutix, Bayer, RemeGen, Roche, Ocuphire Pharma, Adverum Biotechnologies, Boehringer Ingelheim, and others.
- Promising Diabetic Retinopathy Pipeline Therapies in the various stages of development include OTT166, Runcaciguat (BAY1101042), OTX-TKI, OPL-0401, RC28-E injection, EYP-1901, KSI-301, Brolucizumab 6 mg, Entelon Tab. 50mg, and others.
- On August 2023, Bayer announced a study of Phase 2 Clinical Trials for Runcaciguat (BAY1101042). This Phase 2 study is conducted to investigate the safety and efficacy of runcaciguat in the treatment of diabetic retinopathy. To assess efficacy, the retinal morphology will be investigated by 7-field color fundus photography for central assessment of the diabetic retinopathy severity score, or DRSS. Two-step DRSS improvement at 24 weeks of treatment will be the primary efficacy endpoint. DRSS assessments are repeated after completion of 48 weeks of treatment.
- On September 2023, OcuTerra Therapeutics Inc. announced a study of Phase 2 Clinical Trials for OTT166. This study will evaluate the safety and efficacy of OTT166 Ophthalmic solution in participants with Diabetic Retinopathy.
Request a sample and discover the recent advances in Diabetic Retinopathy Treatment Drugs @ Diabetic Retinopathy Pipeline Report
The Diabetic Retinopathy pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Diabetic Retinopathy drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Diabetic Retinopathy clinical trial landscape.
Diabetic Retinopathy Overview
Diabetic retinopathy (DR) is a major complication of diabetes mellitus (DM), which remains a leading cause of visual loss in working-age populations. The retina contains photoreceptor cells that function in the process of visual transduction, i.e., transforming light signals to nerve impulses eventually transmitted from the optic nerve to the brain forming an image.
Find out more about Diabetic Retinopathy Treatment Drugs @ Drugs for Diabetic Retinopathy Treatment
Diabetic Retinopathy Emerging Drugs Profile
- KSI-301: Kodiak Sciences
- Brolucizumab: Novartis
- RGX 314: Regenxbio Inc.
- OTX-TKI: Ocular Therapeutix
- OTT-166: OcuTerra Therapeutics
Diabetic Retinopathy Pipeline Therapeutics Assessment
There are approx. 50+ key companies which are developing the therapies for Diabetic Retinopathy. The Diabetic Retinopathy companies which have their Diabetic Retinopathy drug candidates in the most advanced stage, i.e. phase III include, Kodiak Sciences.
Learn more about the emerging Diabetic Retinopathy Pipeline Therapies @ Diabetic Retinopathy Clinical Trials Assessment
Scope of the Diabetic Retinopathy Pipeline Report
- Coverage- Global
- Encephalopathy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Encephalopathy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Diabetic Retinopathy Companies- Kodiak Sciences, Novartis, Regenxbio Inc., OcuTerra Therapeutics, Ocular Therapeutix, Bayer, RemeGen, Roche, Ocuphire Pharma, Adverum Biotechnologies, Boehringer Ingelheim, and others.
- Diabetic Retinopathy Pipeline Therapies- OTT166, Runcaciguat (BAY1101042), OTX-TKI, OPL-0401, RC28-E injection, EYP-1901, KSI-301, Brolucizumab 6 mg, Entelon Tab. 50mg, and others.
Dive deep into rich insights for new drugs for Diabetic Retinopathy Treatment, Visit @ Diabetic Retinopathy Market Drivers and Barriers, and Future Perspective
Table of Content
- Introduction
- Executive Summary
- Diabetic Retinopathy: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Diabetic Retinopathy– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- KSI-301: Kodiak Sciences
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- RGX 314: Regenxbio Inc
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- OTX-TKI: Ocular Therapeutix
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Drug name: Company name
- Drug profiles in the detailed report…..
- Inactive Products
- Diabetic Retinopathy Key Companies
- Diabetic Retinopathy Key Products
- Diabetic Retinopathy- Unmet Needs
- Diabetic Retinopathy- Market Drivers and Barriers
- Diabetic Retinopathy- Future Perspectives and Conclusion
- Diabetic Retinopathy Analyst Views
- Diabetic Retinopathy Key Companies
- Appendix
For further information on the Diabetic Retinopathy Pipeline therapeutics, reach out to Diabetic Retinopathy Unmet Needs and Analyst Views
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting
){kind=link}